In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
News|Articles|May 22, 2025
Artificial Intelligence Proves Its Worth in Cancer Treatment, Drug Development, and Other Real-World Applications
Author(s)Kyle Doherty
Fact checked by: Caroline Seymour
Multiple experts on artificial intelligence in cancer care discuss its ever-expanding role in several areas of oncology.
Advertisement
Advertisement
As artificial intelligence (AI) seeps more and more into the daily lives of professionals in every industry, cancer care has proven to be no different. In fact, AI-based approaches are already having a dramatic effect on multiple areas of oncology, including treatment selection, the lowering of administrative burden, and drug development.
Related to this article
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Catch up on insights into the global development of breast cancer treatments in the global spotlight.
Ruxolitinib plus extracorporeal photopheresis drove responses in steroid-refractory or -dependent chronic graft-vs-host disease.
An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement